ptn_8k.htm

0001654954-24-008011.txt : 20240621 0001654954-24-008011.hdr.sgml : 20240621 20240621082749 ACCESSION NUMBER: 0001654954-24-008011 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 19 CONFORMED PERIOD OF REPORT: 20240620 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Unregistered Sales of Equity Securities ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240621 DATE AS OF CHANGE: 20240621 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PALATIN TECHNOLOGIES INC CENTRAL INDEX KEY: 0000911216 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 954078884 STATE OF INCORPORATION: NJ FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-15543 FILM NUMBER: 241058393 BUSINESS ADDRESS: STREET 1: 4B CEDAR BROOK DRIVE CITY: CRANBURY STATE: NJ ZIP: 08512 BUSINESS PHONE: 609-495-2200 MAIL ADDRESS: STREET 1: 4B CEDAR BROOK DRIVE CITY: CRANBURY STATE: NJ ZIP: 08512 FORMER COMPANY: FORMER CONFORMED NAME: INTERFILM INC DATE OF NAME CHANGE: 19930825 8-K 1 ptn_8k.htm FORM 8-K ptn_8k.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 21, 2024 (June 20, 2024)

Palatin Technologies, Inc.

(Exact name of registrant as specified in its charter)

Delaware	001-15543	95-4078884
(State or other jurisdiction	(Commission	(IRS employer
of incorporation)	File Number)	identification number)

4B Cedar Brook Drive, Cranbury, NJ		08512
(Address of principal executive offices)		(Zip Code)

Registrant's telephone number, including area code: (609) 495-2200

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class

Trading Symbol

Name of Each Exchange

on Which Registered

Common Stock, par value $0.01 per share

PTN

NYSE American

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.01 Entry into a Material Definitive Agreement.

On June 20, 2024, the Company entered into a letter agreement (the “Inducement Letter”) with a holder (the “Exercising Holder”) of outstanding common stock purchase warrants that the Company issued on November 2, 2022, and October 24, 2023 (the “Existing Warrants”). Pursuant to the Inducement Letter, the Exercising Holder agreed to exercise, for cash, Existing Warrants to purchase, in the aggregate, 3,233,277 shares of common stock in exchange for the Company’s agreement to (i) lower the exercise price to $1.88 per share for the 3,233,277 Existing Warrants being exercised pursuant to the Inducement Letter and (ii) issue to the Exercising Holder an aggregate of 4,849,915 warrants to purchase shares of common stock, comprised of Series A common stock purchase warrants to purchase 2,727,273 shares of common stock (the “Series A Warrants”) and Series B common stock purchase warrants to purchase 2,122,642 (of which 1,624,2021 shares of common stock are subject to Stockholder Approval, as defined below) shares of common stock (the “Series B Warrants” and together with the Series A Warrants, the “Inducement Warrants”). The Company expects to receive aggregate gross proceeds of approximately $6.1 million from the exercise of the Existing Warrants by the Exercising Holder (the “Warrant Inducement”). The Company intends to use the net proceeds for working capital and general corporate purposes.

The issuance of a portion of the shares of common stock underlying the Series B Warrants is subject to stockholder approval under applicable rules and regulations of the NYSE American (“Stockholder Approval” and the date on which Stockholder Approval is received and deemed effective, the “Stockholder Approval Date”). The Company has agreed to convene a stockholders’ meeting on or before the 90^th day following the completion of the Warrant Inducement.

The Inducement Warrants have an exercise price of $1.88 per share and provide for a cashless exercise feature if there is no effective registration statement covering the Inducement Warrants. The Series A Warrants are immediately exercisable and have a term of five years. The Series B Warrants are exercisable for five years, which term of exercise begins on the original issue date with respect to 498,441 Series B Warrants, and on the Stockholder Approval Date with respect to 1,624,201 Series B Warrants.

The Company has agreed to file a registration statement on Form S-3 (or other appropriate form if the Company is not then S-3 eligible) on or before July 30, 2024, to register the resale of the shares of Common Stock (the “Inducement Warrant Shares”) underlying the Inducement Warrants and to use commercially reasonable efforts to cause such registration statement to become effective within 90 days of its initial filing.

The Inducement Letter and forms of Series A Warrant and Series B Warrant are attached as Exhibits 10.1, 4.1, and 4.2, respectively. The description of the terms of the Inducement Letter and the Inducement Warrants is not intended to be complete and is qualified in its entirety by reference to such exhibits. The Inducement Letter contains customary representations, warranties and covenants by the Company which were made only for the purposes of such agreements and as of specific dates, were solely for the benefit of the parties to such agreements and may be subject to limitations agreed upon by the contracting parties.

Item 3.02 Unregistered Sales of Equity Securities.

The Company issued the Inducement Warrants pursuant to the exemption from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), available under Section 4(a)(2). Neither the issuance of the Inducement Warrants nor the Inducement Warrant Shares have been registered under the Securities Act, and such securities may not be offered or sold in the United States absent registration or an exemption from registration under the Securities Act and any applicable state securities laws. The description of the Inducement Warrants under Item 1.01 of this Form 8-K is incorporated by reference herein.

Neither this Current Report on Form 8-K nor any exhibit attached hereto is an offer to sell or the solicitation of an offer to buy securities of the Company.

Item 7.01 Regulation FD Disclosure.

On June 21, 2024, the Company issued a press release announcing the Warrant Inducement, as described above in Item 1.01 of this Current Report on Form 8-K. The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated into this Item 7.01 by reference. This information is not deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not incorporated by reference into any Securities Act registration statements.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

4.1		Form of Series A Warrant

4.2		Form of Series B Warrant

10.1		Inducement Letter, dated June 20, 2024

99.1		Press Release, dated June 21, 2024

104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	PALATIN TECHNOLOGIES, INC.

Date: June 21, 2024	By:	/s/ Stephen T. Wills
		Stephen T. Wills, CPA, MST
		Executive Vice President, Chief Financial Officer and Chief Operating Officer

EX-4.1 2 ptn_ex41.htm FORM OF SERIES A WARRANT ptn_ex41.htm

EXHIBIT 4.1

NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT WITH A REGISTERED BROKER-DEALER OR OTHER LOAN WITH A FINANCIAL INSTITUTION THAT IS AN “ACCREDITED INVESTOR” AS DEFINED IN RULE 501(a) UNDER THE SECURITIES ACT OR OTHER LOAN SECURED BY SUCH SECURITIES.

SERIES A COMMON STOCK PURCHASE WARRANT

PALATIN TECHNOLOGIES, Inc.

Warrant Shares: [•]		Issue Date: June 24, 2024

		Initial Exercise Date: June 24, 2024

THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, Armistice Capital Master Fund Ltd., or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after June 24, 2024 (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on June 24, 2029 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Palatin Technologies, Inc., a Delaware corporation (the “Company”), up to [•] shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).

Section 1. Definitions. Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain Securities Purchase Agreement (the “Purchase Agreement”), dated October 31, 2022, among the Company and the purchasers signatory thereto.

Section 2. Exercise.

a) Exercise of Warrant. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the “Notice of Exercise”). Within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the Warrant Shares specified in the applicable Notice of Exercise by wire transfer or cashier’s check drawn on a United States bank unless the cashless exercise procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise. No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation as soon as reasonably practicable following the date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise within one (1) Trading Day of receipt of such notice. The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.

b) Exercise Price. The exercise price per share of Common Stock under this Warrant shall be $1.88, subject to adjustment hereunder (the “Exercise Price”).

c) Cashless Exercise. If at the time of exercise hereof there is no effective registration statement registering, or the prospectus contained therein is not available for the issuance or resale of the Warrant Shares to or by the Holder, then this Warrant may also be exercised, in whole or in part, at such time by means of a “cashless exercise” in which the Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:

(A) =

as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1) both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening of “regular trading hours” (as defined in Rule 600(b) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the option of the Holder, either (y) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise or (z) the Bid Price of the Common Stock on the principal Trading Market as reported by Bloomberg L.P. (“Bloomberg”) as of the time of the Holder’s execution of the applicable Notice of Exercise if such Notice of Exercise is executed during “regular trading hours” on a Trading Day and is delivered within two (2) hours thereafter (including until two (2) hours after the close of “regular trading hours” on a Trading Day) pursuant to Section 2(a) hereof or (iii) the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section 2(a) hereof after the close of “regular trading hours” on such Trading Day;

(B) =

the Exercise Price of this Warrant, as adjusted hereunder; and

(X) =

the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless exercise.

“Bid Price” means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Holders of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.

“VWAP” means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if the OTCQB Venture Market (“OTCQB”) or the OTCQX Best Market (“OTCQX”) is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Open Market (“Pink Market”) operated by the OTC Markets Group Inc. (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Holders of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.

If Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the Securities Act, the Warrant Shares shall take on the characteristics of the Warrants being exercised, and the holding period of the Warrant Shares being issued may be tacked on to the holding period of this Warrant. The Company agrees not to take any position contrary to this Section 2(c), except to the extent required by applicable law, rule or regulation.

Notwithstanding anything herein to the contrary, on the Termination Date, this Warrant shall be automatically exercised via cashless exercise pursuant to this Section 2(c).

d) Mechanics of Exercise.

i. Delivery of Warrant Shares Upon Exercise. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer Agent to the Holder by crediting the account of the Holder’s or its designee’s balance account with The Depository Trust Company through its Deposit or Withdrawal at Custodian system (“DWAC”) if the Company is then a participant in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares by the Holder or (B) the Warrant Shares are eligible for resale by the Holder without volume or manner-of-sale limitations pursuant to Rule 144 (assuming cashless exercise of the Warrant), and otherwise by physical delivery of a certificate, registered in the Company’s share register in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is the earliest of (i) two (2) Trading Days after the delivery to the Company of the Notice of Exercise, (ii) one (1) Trading Day after delivery of the aggregate Exercise Price to the Company and (iii) the number of Trading Days comprising the Standard Settlement Period after the delivery to the Company of the Notice of Exercise (such date, the “Warrant Share Delivery Date”). Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received by the Warrant Share Delivery Date. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading Day on the third Trading Day after the Warrant Share Delivery Date) for each Trading Day after such Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable. As used herein, “Standard Settlement Period” means the standard settlement period, expressed in a number of Trading Days, on the Company’s primary Trading Market with respect to the Common Stock as in effect on the date of delivery of the Notice of Exercise.

ii. Delivery of New Warrants Upon Exercise. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects be identical with this Warrant.

iii. Rescission Rights. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section 2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.

iv. Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise. In addition to any other rights available to the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date (subject to receipt of the aggregate exercise price for the applicable exercise (other than in the case of a cashless exercise)), and if after such date the Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holder’s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a “Buy-In”), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder’s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit a Holder’s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company’s failure to timely deliver shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.

v. No Fractional Shares or Scrip. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or round up to the next whole share.

vi. Charges, Taxes and Expenses. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; provided, however, that in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.

vii. Closing of Books. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant, pursuant to the terms hereof.

e) Holder’s Exercise Limitations. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder’s Affiliates, and any other Persons acting as a group together with the Holder or any of the Holder’s Affiliates (such Persons, “Attribution Parties”)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates or Attribution Parties. Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder’s determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company’s most recent periodic or annual report filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding. Upon the written or oral request of a Holder, the Company shall within one (1) Trading Day confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported. The “Beneficial Ownership Limitation” shall be [4.99%/9.99%] of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions of this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective until the 61^st day after such notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant.

Section 3. Certain Adjustments.

a) Stock Dividends and Splits. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or re‑classification.

b) Subsequent Rights Offerings. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any class of shares of Common Stock (the “Purchase Rights”), then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (provided, however, that to the extent that the Holder’s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).

c) Pro Rata Distributions. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a “Distribution”), at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (provided, however, that to the extent that the Holder's right to participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).

d) Fundamental Transaction. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company or any Subsidiary, directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of greater than 50% of the voting power of the outstanding common and preferred stock of the Company, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires greater than 50% of the voting power of the outstanding common and preferred stock of the Company (each a “Fundamental Transaction”), then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration (the “Alternate Consideration”) receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of this Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. Notwithstanding anything to the contrary, in the event of a Fundamental Transaction, the Company or any Successor Entity (as defined below) shall, at the Holder’s option, exercisable at any time concurrently with, or within 30 days after, the consummation of the Fundamental Transaction (or, if later, the date of the public announcement of the applicable Fundamental Transaction), purchase this Warrant from the Holder by paying to the Holder an amount of cash equal to the Black Scholes Value (as defined below) of the remaining unexercised portion of this Warrant on the date of the consummation of such Fundamental Transaction; provided, however, that if the Fundamental Transaction is not within the Company's control, including not approved by the Company's Board of Directors, Holder shall only be entitled to receive from the Company or any Successor Entity the same type or form of consideration (and in the same proportion), at the Black Scholes Value of the unexercised portion of this Warrant, that is being offered and paid to the holders of Common Stock of the Company in connection with the Fundamental Transaction, whether that consideration be in the form of cash, stock or any combination thereof, or whether the holders of Common Stock are given the choice to receive from among alternative forms of consideration in connection with the Fundamental Transaction; provided, further, that if holders of Common Stock of the Company are not offered or paid any consideration in such Fundamental Transaction, such holders of Common Stock will be deemed to have received common stock of the Successor Entity (which Entity may be the Company following such Fundamental Transaction) in such Fundamental Transaction. “Black Scholes Value” means the value of this Warrant based on the Black Scholes Option Pricing Model obtained from the “OV” function on Bloomberg determined as of the day of consummation of the applicable Fundamental Transaction for pricing purposes and reflecting (A) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the time between the date of the public announcement of the applicable Fundamental Transaction and the Termination Date, (B) an expected volatility equal to the volatility for the remaining exercised period as obtained from the HVT function on Bloomberg (determined utilizing a 252-day annualization factor) as of the Trading Day immediately following the public announcement of the applicable Fundamental Transaction, (C) the underlying price per share used in such calculation shall be the sum of the price per share being offered in cash, if any, plus the value of any non-cash consideration, if any, being offered in such Fundamental Transaction, (D) a remaining option time equal to the time between the date of the public announcement of the applicable Fundamental Transaction and the Termination Date, and (E) a zero cost of borrow. The payment of the Black Scholes Value will be made by wire transfer of immediately available funds within five (5) Trading Days of the Holder’s election (or, if later, on the effective date of the Fundamental Transaction). The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the “Successor Entity”) to assume in writing all of the obligations of the Company under this Warrant and the other Transaction Documents in accordance with the provisions of this Section 3(d) pursuant to written agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall be added to the term “Company” under this Warrant (so that from and after the occurrence or consummation of such Fundamental Transaction, each and every provision of this Warrant and the other Transaction Documents referring to the “Company” shall refer instead to each of the Company and the Successor Entity or Successor Entities, jointly and severally), and the Successor Entity or Successor Entities, jointly and severally with the Company, may exercise every right and power of the Company prior thereto and the Successor Entity or Successor Entities shall assume all of the obligations of the Company prior thereto under this Warrant and the other Transaction Documents with the same effect as if the Company and such Successor Entity or Successor Entities, jointly and severally, had been named as the Company herein.

e) Calculations. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.

f) Notice to Holder.

i. Adjustment to Exercise Price. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly deliver to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.

ii. Notice to Allow Exercise by Holder. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with any reclassification of the Common Stock, any consolidation or merger to which the Company (or any of its Subsidiaries) is a party, any sale or transfer of all or substantially all of its assets, or any compulsory share exchange whereby the Common Stock is converted into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by email to the Holder at its last email address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.

Section 4. Transfer of Warrant.

a) Transferability. Subject to compliance with any applicable securities laws and the conditions set forth in Section 4(d) hereof and to the provisions of Section 4.1 of the Purchase Agreement, this Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant to the Company within three (3) Trading Days of the date on which the Holder delivers an assignment form to the Company assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued.

b) New Warrants. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the Issue Date of this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.

c) Warrant Register. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the “Warrant Register”), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary.

d) Transfer Restrictions. If, at the time of the surrender of this Warrant in connection with any transfer of this Warrant, the transfer of this Warrant shall not be either (i) registered pursuant to an effective registration statement under the Securities Act and under applicable state securities or blue sky laws or (ii) eligible for resale without volume or manner-of-sale restrictions or current public information requirements pursuant to Rule 144, the Company may require, as a condition of allowing such transfer, that the Holder or transferee of this Warrant, as the case may be, comply with the provisions of Section 5.7 of the Purchase Agreement.

e) Representation by the Holder. The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Warrant and, upon any exercise hereof, will acquire the Warrant Shares issuable upon such exercise, for its own account and not with a view to or for distributing or reselling such Warrant Shares or any part thereof in violation of the Securities Act or any applicable state securities law, except pursuant to sales registered or exempt under the Securities Act.

Section 5. Miscellaneous.

a) No Rights as Stockholder Until Exercise; No Settlement in Cash. This Warrant does not entitle the Holder to any voting rights, dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set forth in Section 3. Without limiting any rights of a Holder to receive Warrant Shares on a “cashless exercise” pursuant to Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in no event shall the Company be required to net cash settle an exercise of this Warrant.

b) Loss, Theft, Destruction or Mutilation of Warrant. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.

c) Saturdays, Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Trading Day, then such action may be taken or such right may be exercised on the next succeeding Trading Day.

d) Authorized Shares.

The Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such issue).

Except and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this Warrant.

Before taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction thereof.

e) Jurisdiction. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined in accordance with the provisions of the Purchase Agreement.

f) Restrictions. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.

g) Nonwaiver and Expenses. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as a waiver of such right or otherwise prejudice the Holder’s rights, powers or remedies. Without limiting any other provision of this Warrant or the Purchase Agreement, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys’ fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.

h) Notices. Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall be delivered in accordance with the notice provisions of the Purchase Agreement.

i) Limitation of Liability. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the Company.

j) Remedies. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate.

k) Successors and Assigns. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable by the Holder or holder of Warrant Shares.

l) Amendment. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company, on the one hand, and the Holder of this Warrant, on the other hand.

m) Severability. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.

n) Headings. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.

********************

(Signature Page Follows)

IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.

	PALATIN TECHNOLOGIES, Inc.

	By:
		Name: Title:

NOTICE OF EXERCISE

To: PALATIN TECHNOLOGIES, Inc.

(1) The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.

(2) Payment shall take the form of (check applicable box):

[ ] in lawful money of the United States; or

[ ] if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c).

(3) Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:

_______________________________

The Warrant Shares shall be delivered to the following DWAC Account Number:

_______________________________

(4) Accredited Investor. The undersigned is an “accredited investor” as defined in Regulation D promulgated under the Securities Act of 1933, as amended.

[SIGNATURE OF HOLDER]

Name of Investing Entity: _____________________________________________________________________________________

Signature of Authorized Signatory of Investing Entity: _______________________________________________________________

Name of Authorized Signatory: _________________________________________________________________________________

Title of Authorized Signatory: __________________________________________________________________________________

Date: _____________________________________________________________________________________________________

EXHIBIT B

ASSIGNMENT FORM

(To assign the foregoing Warrant, execute this form and supply required information. Do not use this form to exercise the Warrant to purchase shares.)

FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to

Name:
	(Please Print)
Address:
	(Please Print)
Phone Number:

Email Address:

Dated: _____________________ ____, ____________
Holder’s Signature:
Holder’s Address:

EX-4.2 3 ptn_ex42.htm FORM OF SERIES B WARRANT ptn_ex42.htm

EXHIBIT 4.2

SERIES B COMMON STOCK PURCHASE WARRANT

PALATIN TECHNOLOGIES, Inc.

Warrant Shares: [•]		Issue Date: June 24, 2024

Stockholder Approval Warrants: [•]		Initial Exercise Date: June 24, 2024
	(other than the Stockholder Approval Warrants)

THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [•] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after June 24, 2024 (the “Initial Exercise Date”) (except that [•] shares of Common Stock shall be exercisable for a period of five (5) years commencing on or after the Stockholder Approval Date) (the “Stockholder Approval Warrants”) and on or prior to 5:00 p.m. (New York City time) on June 24, 2029 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Palatin Technologies, Inc., a Delaware corporation (the “Company”), up to [ ] shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).

Section 1. Definitions. Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain Securities Purchase Agreement (the “Purchase Agreement”), dated October 20, 2023, among the Company and the purchasers signatory thereto, except:

“Stockholder Approval” refers to when the Company has received approval to issue the Stockholder Approval Warrants.

“Stockholder Approval Date” means the date on which Stockholder Approval is received and deemed effective.

Section 2. Exercise.

a) Exercise of Warrant. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after the Initial Exercise Date (or the Stockholder Approval Date for the Stockholder Approval Warrants) and on or before the Termination Date by delivery to the Company of a duly executed PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the “Notice of Exercise”). Within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the Warrant Shares specified in the applicable Notice of Exercise by wire transfer or cashier’s check drawn on a United States bank unless the cashless exercise procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise. No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation as soon as reasonably practicable following the date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise within one (1) Trading Day of receipt of such notice. The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.

b) Exercise Price. The exercise price per share of Common Stock under this Warrant shall be $1.88, subject to adjustment hereunder (the “Exercise Price”).

(A) =

(B) =

the Exercise Price of this Warrant, as adjusted hereunder; and

(X) =

Notwithstanding anything herein to the contrary, on the Termination Date, this Warrant shall be automatically exercised via cashless exercise pursuant to this Section 2(c).

d) Mechanics of Exercise.

vii. Closing of Books. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant, pursuant to the terms hereof.

Section 3. Certain Adjustments.

a) Stock Dividends and Splits. If the Company, at any time while this Warrant is outstanding (and following the Stockholder Approval Date with respect to the Stockholder Approval Warrants): (i) pays a stock dividend or otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or re‑classification.

b) Subsequent Rights Offerings. In addition to any adjustments pursuant to Section 3(a) above (and following the Stockholder Approval Date with respect to the Stockholder Approval Warrants), if at any time the Company grants, issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any class of shares of Common Stock (the “Purchase Rights”), then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (provided, however, that to the extent that the Holder’s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).

c) Pro Rata Distributions. During such time as this Warrant is outstanding (and following the Stockholder Approval Date with respect to the Stockholder Approval Warrants), if the Company shall declare or make any dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a “Distribution”), at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (provided, however, that to the extent that the Holder's right to participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).

f) Notice to Holder.

Section 4. Transfer of Warrant.

Section 5. Miscellaneous.

d) Authorized Shares.

e) Jurisdiction. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined in accordance with the provisions of the Purchase Agreement.

l) Amendment. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company, on the one hand, and the Holder of this Warrant, on the other hand.

n) Headings. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.

********************

(Signature Page Follows)

IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.

	PALATIN TECHNOLOGIES, Inc.

	By:
		Name: Title:

NOTICE OF EXERCISE

To: PALATIN TECHNOLOGIES, Inc.

(2) Payment shall take the form of (check applicable box):

[ ] in lawful money of the United States; or

(3) Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:

_______________________________

The Warrant Shares shall be delivered to the following DWAC Account Number:

_______________________________

(4) Accredited Investor. The undersigned is an “accredited investor” as defined in Regulation D promulgated under the Securities Act of 1933, as amended.

[SIGNATURE OF HOLDER]

Name of Investing Entity: _____________________________________________________________________________________

Signature of Authorized Signatory of Investing Entity: _______________________________________________________________

Name of Authorized Signatory: _________________________________________________________________________________

Title of Authorized Signatory: __________________________________________________________________________________

Date: _____________________________________________________________________________________________________

EXHIBIT B

ASSIGNMENT FORM

(To assign the foregoing Warrant, execute this form and supply required information. Do not use this form to exercise the Warrant to purchase shares.)

FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to

Name:
	(Please Print)
Address:
	(Please Print)
Phone Number:

Email Address:

Dated: _____________________ ____, ____________
Holder’s Signature:
Holder’s Address:

EX-10.1 4 ptn_ex101.htm INDUCEMENT LETTER ptn_ex101.htm

EXHIBIT 10.1

PALATIN TECHNOLOGIES, INC.

4B Cedar Brook Drive

Cranbury, New Jersey 08512

June 20, 2024

To the Holder of Common Stock Purchase Warrants

Re:	Inducement Offer to Exercise Existing Common Stock Purchase Warrants

Dear Holder:

PALATIN TECHNOLOGIES, INC. (the “Company”) is pleased to offer (this “Inducement Offer”) to you (“Holder”, “you” or similar terminology) the opportunity to receive new warrants to purchase up to a number of shares (the “New Warrant Shares”) of Common Stock, par value $0.01 per share (the “Common Stock”), equal to 150% of the number of shares of common stock issuable to you pursuant to upon the exercise of that certain Warrant to Purchase Shares of Common Stock issued to you on November 2, 2022 (“Existing November 2022 Common Warrants”), and 150% of the number of shares of common stock issuable to you pursuant to upon the exercise of that certain Warrant to Purchase Shares of Common Stock issued to you on October 24, 2023 (“Existing October 2023 Common Warrants,” and together with the Existing November 2022 Common Warrants, the (“Existing Common Warrants”), as more particularly set forth on the signature page hereto, in consideration for exercising for cash any or all such Existing Common Warrants. The issuance, or resale, of shares of Common Stock underlying the Existing Common Warrants have been registered pursuant to effective registration statements (Files No. 333-262555 and 333-275883). The shares of Common Stock underlying the Existing Common Warrants are referred to herein as the “Warrant Shares” and the registration statements referenced in the foregoing sentence are referred to herein as the “Registration Statements.” The Registration Statements are currently effective and, upon exercise of the Existing Common Warrants pursuant to this letter agreement (the “Inducement Agreement,” and together with the Existing Common Warrants and the New Warrants (as defined below), the “Transaction Documents”), will be effective for the issuance or resale of the Warrant Shares, as applicable. Capitalized terms not otherwise defined herein shall have the meanings set forth in the New Warrants (as defined hereinafter).

The Company is making you this offer during the period from the date of this Inducement Offer set forth above and until 8:30 am, Eastern Time, on June 21, 2024 (the “Exercise Period”). Exercise of the Existing Common Warrants may be made, in whole or in part, at any time or times during the Exercise Period by delivery to the Company of a duly executed facsimile copy or PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise attached to the Existing Common Warrants, as applicable; provided, that the exercise of Existing Common Warrants will be accompanied by payment in full of the Reduced Exercise Price (as defined below) to the Company.

The Company desires to reduce the Exercise Price of the Existing Common Warrants to $1.88 per share (the “Reduced Exercise Price”). In consideration for exercising Existing Common Warrants held by Holder pursuant to the terms of this Inducement Offer (the “Warrant Exercise”), the Company hereby offers to issue you or your designees:

(a) for exercising Existing November 2022 Common Warrants, a Series A Common Stock Purchase Warrant (the “Series A Warrant”) to purchase up to a number of shares of Common Stock equal to 150% of the number of Warrant Shares issued pursuant to such exercise of Existing November 2022 Common Warrants, which Series A Warrants shall be substantially in the form as set forth in Exhibit A hereto; and

(b) for exercising Existing October 2023 Common Warrants, a Series B Common Stock Purchase Warrant (the “Series B Warrant”) to purchase up to a number of shares of Common Stock equal to 150% of the number of Warrant Shares issued pursuant to such exercise of Existing October 2023 Common Warrants, which Series B Warrants shall be substantially in the form as set forth in Exhibit B hereto.

The New Warrant certificates will be delivered within one (1) Trading Day following the Warrant Exercise, and such New Warrants, together with any underlying shares of Common Stock issued upon exercise of the New Warrants, shall, unless and until registered, contain customary restrictive legends and other language typical for an unregistered warrant and unregistered shares. Notwithstanding anything herein to the contrary, in the event that any Warrant Exercise would otherwise cause the Holder to exceed the beneficial ownership limitations (“Beneficial Ownership Limitation”) set forth in Section 2(e) of the Existing Common Warrants (or, if applicable and at the Holder’s election, 9.99%), the Company shall only issue such number of Warrant Shares to the Holder that would not cause the Holder to exceed the maximum number of Warrant Shares permitted thereunder, as directed by the Holder, with the balance to be held in abeyance until notice from the Holder that the balance (or portion thereof) may be issued in compliance with such limitations, which abeyance shall be evidenced through the Existing Common Warrants which shall be deemed prepaid thereafter (including the payment in full of the exercise price), and exercised pursuant to a Notice of Exercise in the Existing Common Warrants (provided no additional exercise price shall be due and payable). The parties hereby agree that the Beneficial Ownership Limitation for purposes of the Existing Common Warrants is as set forth on the Holder’s signature page hereto.

Expressly subject to the paragraph immediately following this paragraph below, Holder may accept this offer by signing this letter below, which constitutes the Holder’s acceptance to exercise Existing Common Warrants at the Holder’s own discretion subject to the Beneficial Ownership Limitation set forth in Section 2(e) of the Existing Common Warrants.

The Company agrees to the representations, warranties and covenants set forth on Annex A attached hereto.

The Holder represents and warrants that, as of the date hereof, the Holder is fully aware of, and has reviewed all of the Company’s public filings.

Holder represents and warrants that, as of the date hereof it is, and on each date on which it exercises any New Warrants it will be, an “accredited investor” as defined in Rule 501 of Regulation D promulgated under the Securities Act, and agrees that the New Warrants will contain restrictive legends when issued, and neither the New Warrants nor the shares of Common Stock issuable upon exercise of the New Warrants will be registered under the Securities Act, except as provided in Annex A attached hereto. Also, Holder represents and warrants that it is acquiring the New Warrants as principal for its own account and has no direct or indirect arrangement or understandings with any other persons to distribute or regarding the distribution of the New Warrants or the New Warrant Shares (this representation is not limiting Holder’s right to sell the New Warrant Shares pursuant to an effective registration statement under the Securities Act or otherwise in compliance with applicable federal and state securities laws).

The Holder understands that the New Warrants and the New Warrant Shares are not, and may never be, registered under the Securities Act, or the securities laws of any state and, accordingly, each certificate, if any, representing such securities shall bear a legend substantially similar to the following:

“THIS SECURITY HAS NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS.”

Upon the Holder’s exercise of the New Warrants, certificates evidencing the New Warrant Shares shall not contain any legend (including the legend set forth above), (i) while a registration statement covering the resale of such New Warrant Shares is effective under the Securities Act, (ii) following any sale of such New Warrant Shares pursuant to Rule 144 under the Securities Act, (iii) if such New Warrant Shares are eligible for sale under Rule 144 (assuming cashless exercise of the New Warrants), without the requirement for the Company to be in compliance with the current public information requirement under Rule 144 as to such New Warrant Shares and without volume or manner-of-sale restrictions, (iv) if such New Warrant Shares may be sold under Rule 144 (assuming cashless exercise of the New Warrants) and the Company is then in compliance with the current public information requirement under Rule 144 as to such New Warrant Shares, or (v) if such legend is not required under applicable requirements of the Securities Act (including judicial interpretations and pronouncements issued by the staff of the Securities and Exchange Commission (the “Commission”) and the earliest of clauses (i) through (v), the “Delegend Date”)). The Company shall cause its counsel to issue a legal opinion to the Transfer Agent promptly after the Delegend Date if required by the Company and/or the Transfer Agent to effect the removal of the legend hereunder, or at the request of the Holder, which opinion shall be in form and substance reasonably acceptable to the Holder. From and after the Delegend Date, such New Warrant Shares shall be issued free of all legends, provided that, upon request of the Company (which request shall also include a form of customary representation letter), the Holder has delivered in advance to the Company a customary representation letter that is reasonably satisfactory to the Company and its counsel. The Company agrees that following the Delegend Date or at such time as such legend is no longer required under this Section, it will, no later than two (2) Trading Days following the delivery by the Holder to the Company or the Transfer Agent of a certificate representing the New Warrant Shares issued with a restrictive legend (such second (2^nd) Trading Day, the “Legend Removal Date”), deliver or cause to be delivered to the Holder a certificate representing such shares that is free from all restrictive and other legends or, at the request of the Holder, shall credit the account of the Holder’s prime broker with the Depository Trust Company System as directed by the Holder.

In addition to the Holder’s other available remedies, the Company shall pay to a Holder, in cash, (i) as partial liquidated damages and not as a penalty, for each $1,000 of New Warrant Shares (based on the VWAP of the Common Stock on the date such New Warrant Shares are submitted to the Transfer Agent) delivered for removal of the restrictive legend, $10 per Trading Day (increasing to $20 per Trading Day five (5) Trading Days after such damages have begun to accrue) for each Trading Day after the Legend Removal Date until such certificate is delivered without a legend and (ii) if the Company fails to (a) issue and deliver (or cause to be delivered) to the Holder by the Legend Removal Date a certificate representing the New Warrant Shares free from all restrictive and other legends and (b) if after the Legend Removal Date the Holder purchases (in an open market transaction or otherwise) shares of Common Stock to deliver in satisfaction of a sale by the Holder of all or any portion of the number of shares of Common Stock, or a sale of a number of shares of Common Stock equal to all or any portion of the number of shares of Common Stock that the Holder anticipated receiving from the Company without any restrictive legend, then, an amount equal to the excess of the Holder’s total purchase price (including brokerage commissions and other out-of-pocket expenses, if any) for the shares of Common Stock so purchased (including brokerage commissions and other out-of-pocket expenses, if any) (the “Buy-In Price”) over the product of (A) such number of New Warrant Shares that the Company was required to deliver to the Holder by the Legend Removal Date and for which the Holder was required to purchase shares to timely satisfy delivery requirements, multiplied by (B) the weighted average price at which the Holder sold that number of shares of Common Stock.

If this offer is accepted and the transaction documents are executed, then on or before 8:30 a.m., Eastern Time, on the Trading Day following the date hereof, the Company shall issue a press release and/or file a Current Report on Form 8-K with the Securities and Exchange Commission (the “Commission”) disclosing all material terms of the transactions contemplated hereunder, including this letter agreement as an exhibit thereto with the Commission. From and after the issuance of such press release or filing of such Current Report on Form 8-K, as applicable, the Company represents to you that it shall have publicly disclosed all material, non-public information delivered to you by the Company, or any of its respective officers, directors, employees or agents in connection with the transactions contemplated hereunder. In addition, effective upon the issuance of such press release and/or filing of such Current Report on Form 8-K, the Company acknowledges and agrees that any and all confidentiality or similar obligations under any agreement, whether written or oral, between the Company, any of its Subsidiaries or any of their respective officers, directors, agents, employees or Affiliates on the one hand, and you and your Affiliates on the other hand, shall terminate. The Company represents, warrants and covenants that, upon acceptance of this offer, and upon issuance of the Warrant Shares, the Warrant Shares shall be issued free of any legends or restrictions on resale by Holder.

No later than the first (1^st) Trading Day following the date hereof, the closing (“Closing”) shall occur at such location as the parties shall mutually agree. Settlement of the Warrant Shares shall occur via “Delivery Versus Payment” (“DVP”) (i.e., on the Closing Date, the Company shall issue the Warrant Shares registered in the Holder’s name and address provided to the Company in writing and released by the Transfer Agent directly to the account(s) at the Placement Agent identified by the Holder; upon receipt of such Warrant Shares, the Placement Agent shall promptly electronically deliver such Warrant Shares to the Holder, and payment therefor shall concurrently be made to the Company by the Placement Agent (or its clearing firm) by wire transfer to the Company). The date of the Closing of the exercise of the Existing Common Warrants shall be referred to as the “Closing Date”.

	Sincerely yours,

	PALATIN TECHNOLOGIES, INC.

	By:
	Name:
	Title:

[Holder Signature Page Follows]

Accepted and Agreed to:

Name of Holder: _________________________________________________

Signature of Authorized Signatory of Holder: _________________________________________________

Name of Authorized Signatory: _________________________________________________

Title of Authorized Signatory: _________________________________________________

Number of Existing November 2022 Warrants: ________________________________________________

Number of Existing October 2023 Warrants: ( shares of Common Stock subject to Stockholder Approval)

Aggregate Warrant Exercise Price at the Reduced Exercise Price being exercised contemporaneously with signing this letter agreement: _________________________________________________

Existing November 2022 Warrants Beneficial Ownership Blocker: 4.99% or 9.99%

Existing October 2023 Warrants Beneficial Ownership Blocker: 4.99% or 9.99%

New Series A Common Warrants Beneficial Ownership Blocker: 4.99% or 9.99%

New Series B Common Warrants Beneficial Ownership Blocker: 4.99% or 9.99%

DTC Instructions: _________________________________________________

Annex A

Representations, Warranties and Covenants of the Company. The Company hereby makes the following representations and warranties to the Holder:

a) Subsidiaries. All of the direct and indirect subsidiaries of the Company are set forth on the SEC Reports. The Company owns, directly or indirectly, all of the capital stock or other equity interests of each subsidiary free and clear of any liens, and all of the issued and outstanding shares of capital stock of each subsidiary are validly issued and are fully paid, non-assessable and free of preemptive and similar rights to subscribe for or purchase securities.

b) SEC Reports. The Company has filed all reports, schedules, forms, statements and other documents required to be filed by the Company under the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, for the two years preceding the date hereof (or such shorter period as the Company was required by law or regulation to file such material) (the foregoing materials, including the exhibits thereto and documents incorporated by reference therein “SEC Reports”). As of their respective dates, the SEC Reports complied in all material respects with the requirements of the Exchange Act and none of the SEC Reports, when filed, contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading except as otherwise noted in a subsequent SEC Report. The Company has never been an issuer subject to Rule 144(i) under the Securities Act.

c) Authorization; Enforcement. The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated by this letter agreement and otherwise to carry out its obligations hereunder. The execution and delivery of this letter agreement by the Company and the consummation by the Company of the transactions contemplated hereby have been duly authorized by all necessary action on the part of the Company and no further action is required by the Company, its board of directors or its stockholders in connection herewith, other than the Stockholder Approval (as defined in the Series B Warrants). This letter agreement has been duly executed by the Company and, when delivered in accordance with the terms hereof, will constitute the valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors’ rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable law.

d) No Conflicts. The execution, delivery and performance of this letter agreement by the Company and the consummation by the Company of the transactions contemplated hereby do not and will not: (i) conflict with or violate any provision of the Company’s certificate or articles of incorporation, bylaws or other organizational or charter documents; or (ii) conflict with, or constitute a default (or an event that with notice or lapse of time or both would become a default) under, result in the creation of any liens, claims, security interests, other encumbrances or defects upon any of the properties or assets of the Company in connection with, or give to others any rights of termination, amendment, acceleration or cancellation (with or without notice, lapse of time or both) of, any material agreement, credit facility, debt or other material instrument (evidencing Company debt or otherwise) or other material understanding to which such Company is a party or by which any property or asset of the Company is bound or affected; or (iii) conflict with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority to which the Company is subject (including federal and state securities laws and regulations), or by which any property or asset of the Company is bound or affected, except, in the case of each of clauses (ii) and (iii), such as could not have or reasonably be expected to result in a material adverse effect upon the business, prospects, properties, operations, condition (financial or otherwise) or results of operations of the Company, taken as a whole, or in its ability to perform its obligations under this letter agreement.

e) Registration Obligations. On or before July 30, 2024, the Company shall file with the Commission a registration statement on Form S-3 (or other appropriate form if the Company is not then Form S-3 eligible) providing for the resale of the New Warrant Shares by the holders of the New Warrants (the “Resale Registration Statement”). The Company shall use commercially reasonable efforts to cause the Resale Registration Statement to become effective within 90 calendar days following the date of filing with the Commission and to keep the Resale Registration Statement effective at all times until no holder of the New Warrants owns any New Warrants or New Warrant Shares.

f) Trading Market. Except for as related to the Stockholder Approval, the transactions contemplated under this letter agreement comply with all the rules and regulations of NYSE American.

g) Filings, Consents and Approvals. The Company is not required to obtain any consent, waiver, authorization or order of, give any notice to, or make any filing or registration with, any court or other federal, state, local or other governmental authority or other Person in connection with the execution, delivery and performance by the Company of this letter agreement, other than: (i) the filings required pursuant to this letter agreement; (ii) application(s) or notice to each applicable Trading Market for the listing of the New Warrants and New Warrant Shares for trading thereon in the time and manner required thereby, and (iii) the filing of form D with the Commission and such filings as are required to be made under applicable state securities laws.

h) Listing of Common Stock. The Company agrees that if the Company applies to have the Common Stock traded on any other Trading Market, it will then include in such application all of the New Warrant Shares, and will take such other action as is necessary to cause all of the New Warrant Shares to be listed or quoted on such other Trading Market as promptly as possible. The Company will then take all action reasonably necessary to continue the listing and trading of its Common Stock on a Trading Market and will comply in all respects with the Company’s reporting, filing and other obligations under the bylaws or rules of the Trading Market. The Company agrees to maintain the eligibility of the Common Stock for electronic transfer through the Depository Trust Company or another established clearing corporation, including, without limitation, by timely payment of fees to the Depository Trust Company or such other established clearing corporation in connection with such electronic transfer. In addition, and if applicable, the Company shall hold an annual or special meeting of stockholders on or prior to the date that is ninety (90) days following the Closing Date for the purpose of obtaining Stockholder Approval, with the recommendation of the Company’s Board of Directors that such proposals are approved, and the Company shall solicit proxies from its stockholders in connection therewith in the same manner as all other management proposals in such proxy statement and all management-appointed proxyholders shall vote their proxies in favor of such proposals. If the Company does not obtain Stockholder Approval at the first meeting, the Company shall call a meeting every ninety (90) days thereafter to seek Stockholder Approval until the earlier of the date on which Stockholder Approval is obtained or the New Warrants are no longer outstanding. The Company shall set the record date for Stockholder Approval prior to the Closing Date.

i) Subsequent Equity Sales.

a. From the date hereof until sixty (60) days after the Closing Date neither the Company nor any Subsidiary shall (A) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any Common Stock or Common Stock Equivalents or (B) file any registration statement or any amendment or supplement to any existing registration statement (other than (x) the Resale Registration Statement referred to herein, or (y) prospectus supplement to the Registration Statement to reflect the transactions contemplated hereby, or (z) filing a registration statement on Form S-8 in connection with any employee benefit plan. Notwithstanding the foregoing, this Section (h)(i) shall not apply in respect of an Exempt Issuance. “Exempt Issuance” means the issuance of (a) shares of Common Stock or options to employees, officers or directors of the Company pursuant to any stock or option plan duly adopted for such purpose, by a majority of the non-employee members of the Board of Directors or a majority of the members of a committee of non-employee directors established for such purpose for services rendered to the Company, (b) the shares of Common Stock issuable upon the exercise or exchange of or conversion of any securities issued hereunder and/or other securities exercisable or exchangeable for or convertible into shares of Common Stock issued and outstanding on the date of this letter agreement, provided that such securities have not been amended since the date of this letter agreement to increase the number of such securities or to decrease the exercise price, exchange price or conversion price of such securities (other than in connection with stock splits or combinations) or to extend the term of such securities, (c) securities issued pursuant to acquisitions or strategic transactions approved by a majority of the disinterested directors of the Company, provided that such securities are issued as “restricted securities” (as defined in Rule 144) and carry no registration rights that require or permit the filing of any registration statement in connection therewith during the prohibition period this Section (h)(i), and provided that any such issuance shall only be to a Person (or to the equityholders of a Person) which is, itself or through its subsidiaries, an operating company or an owner of an asset in a business synergistic with the business of the Company and shall provide to the Company additional benefits in addition to the investment of funds, but shall not include a transaction in which the Company is issuing securities primarily for the purpose of raising capital or to an entity whose primary business is investing in securities, and (d) any securities pursuant to transactions that qualify as “exempt issuances” that are as defined and permitted pursuant to any currently outstanding agreements of the Company. “Person” means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind, for purposes of this Section (h)(i).

b. From the date hereof until six (6) months following the Closing Date, the Company shall be prohibited from effecting or entering into an agreement to effect any issuance by the Company nor any Subsidiary of Common Stock or Common Stock Equivalents (or a combination of units thereof) involving a Variable Rate Transaction. “Variable Rate Transaction” means a transaction in which the Company (i) issues or sells any debt or equity securities that are convertible into, exchangeable or exercisable for, or include the right to receive, additional shares of Common Stock either (A) at a conversion price, exercise price or exchange rate or other price that is based upon, and/or varies with, the trading prices of or quotations for the shares of Common Stock at any time after the initial issuance of such debt or equity securities or (B) with a conversion, exercise or exchange price that is subject to being reset at some future date after the initial issuance of such debt or equity security or upon the occurrence of specified or contingent events directly or indirectly related to the business of the Company or the market for the Common Stock or (ii) enters into, or effects a transaction under, any agreement, including, but not limited to, an equity line of credit or an “at-the-market offering”, whereby the Company may issue securities at a future determined price, regardless of whether shares pursuant to such agreement have actually been issued and regardless of whether such agreement is subsequently canceled provided, however, that, after ninety 90 days following the Closing Date, the issuance of shares of Common Stock in an “at-the-market” offering shall not be deemed a Variable Rate Transaction. The Holder shall be entitled to obtain injunctive relief against the Company to preclude any such issuance, which remedy shall be in addition to any right to collect damages.

j) Form D; Blue Sky Filings. If required, the Company agrees to timely file a Form D with respect to the New Warrants and New Warrant Shares as required under Regulation D and to provide a copy thereof, promptly upon request of any Purchaser. The Company shall take such action as the Company shall reasonably determine is necessary in order to obtain an exemption for, or to qualify the New Warrants and New Warrant Shares for, sale to the Holder at Closing under applicable securities or “Blue Sky” laws of the states of the United States, and shall provide evidence of such actions promptly upon request of any Holder.

k) Capitalization. Since the Company’s most recently filed quarterly report under the Exchange Act on May 15, 2024, the Company has not issued any capital stock, other than pursuant to the exercise of employee stock options under the Company’s stock option plans, the issuance of shares of Common Stock to employees pursuant to the Company’s employee stock purchase plans, and pursuant to the conversion and/or exercise of Common Stock Equivalents outstanding as of the date of the most recently filed periodic report under the Exchange Act. No Person has any right of first refusal, preemptive right, right of participation, or any similar right to participate in the transactions contemplated by the Transaction Documents. Except as a result of the purchase and sale of the Securities and as set forth on the SEC Reports, there are no outstanding options, warrants, scrip rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities, rights or obligations convertible into or exercisable or exchangeable for, or giving any Person any right to subscribe for or acquire, any shares of Common Stock or the capital stock of any Subsidiary, or contracts, commitments, understandings or arrangements by which the Company or any Subsidiary is or may become bound to issue additional shares of Common Stock or Common Stock Equivalents or capital stock of any Subsidiary. The issuance and sale of the Securities will not obligate the Company or any Subsidiary to issue shares of Common Stock or other securities to any Person (other than the Purchasers and the Placement Agent) and will not result in a right of any holder of Company securities to adjust the exercise, conversion, exchange or reset price under any of such securities. There are no outstanding securities or instruments of the Company or any Subsidiary with any provision that adjusts the exercise, conversion, exchange or reset price of such security or instrument upon an issuance of securities by the Company or any Subsidiary. There are no outstanding securities or instruments of the Company or any Subsidiary that contain any redemption or similar provisions, and there are no contracts, commitments, understandings or arrangements by which the Company or any Subsidiary is or may become bound to redeem a security of the Company or such Subsidiary. Other than as disclosed in the SEC Reports, the Company does not have any stock appreciation rights or “phantom stock” plans or agreements or any similar plan or agreement. All of the outstanding shares of capital stock of the Company are duly authorized, validly issued, fully paid and nonassessable, have been issued in compliance with all applicable federal and state securities laws, and none of such outstanding shares was issued in violation of any preemptive rights or similar rights to subscribe for or purchase securities. No further approval or authorization of any stockholder, the Board of Directors or others is required for the issuance and sale of the Securities. There are no stockholders agreements, voting agreements or other similar agreements with respect to the Company’s capital stock to which the Company is a party or, to the knowledge of the Company, between or among any of the Company’s stockholders. For purposes hereof, “Common Stock Equivalents” means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.

l) Material Changes; Undisclosed Events, Liabilities or Developments. Since the date of the latest audited financial statements included within the SEC Reports, (i) there has been no event, occurrence or development that has had or that could reasonably be expected to result in a Material Adverse Effect, (ii) the Company has not incurred any liabilities (contingent or otherwise) other than (A) trade payables and accrued expenses incurred in the ordinary course of business consistent with past practice and (B) liabilities not required to be reflected in the Company’s financial statements pursuant to GAAP or disclosed in filings made with the Commission, (iii) the Company has not altered its method of accounting, (iv) the Company has not declared or made any dividend or distribution of cash or other property to its stockholders or purchased, redeemed or made any agreements to purchase or redeem any shares of its capital stock and (v) the Company has not issued any equity securities to any officer, director or Affiliate, except pursuant to existing Company stock incentive plans. The Company does not have pending before the Commission any request for confidential treatment of information. Except for the issuance of the Securities contemplated by this Agreement or as set forth on the SEC Reports, no event, liability, fact, circumstance, occurrence or development has occurred or exists or is reasonably expected to occur or exist with respect to the Company or its Subsidiaries or their respective businesses, prospects, properties, operations, assets or financial condition that would be required to be disclosed by the Company under applicable securities laws at the time this representation is made or deemed made that has not been publicly disclosed at least 1 Trading Day prior to the date that this representation is made. For purposes hereof, “Material Adverse Effect” means (i) a material adverse effect on the legality, validity or enforceability of the Transaction Documents, (ii) a material adverse effect on the results of operations, assets, business, prospects or condition (financial or otherwise) of the Company and the subsidiaries, taken as a whole, or (iii) a material adverse effect on the Company’s ability to perform in any material respect on a timely basis its obligations under any Transaction Document.

m) Registration Rights. Except as set forth on the SEC Reports, no Person has any right to cause the Company or any subsidiary to effect the registration under the Securities Act, of any securities of the Company or any subsidiary.

n) Listing and Maintenance Requirements. The Common Stock is registered pursuant to Section 12(b) or 12(g) of the Exchange Act, and the Company has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the registration of the Common Stock under the Exchange Act nor has the Company received any notification that the Commission is contemplating terminating such registration. Except as set forth on the SEC Reports, the Company has not, in the 12 months preceding the date hereof, received notice from any Trading Market on which the Common Stock is or has been listed or quoted to the effect that the Company is not in compliance with the listing or maintenance requirements of such Trading Market. The Company is, and has no reason to believe that it will not in the foreseeable future continue to be, in material compliance with all such listing and maintenance requirements. The Common Stock is currently eligible for electronic transfer through the Depository Trust Company or another established clearing corporation and the Company is current in payment of the fees to the Depository Trust Company (or such other established clearing corporation) in connection with such electronic transfer.

o) Solvency. Based on the consolidated financial condition of the Company, after giving effect to the receipt by the Company of the proceeds from the sale of the Securities hereunder, (i) the fair saleable value of the Company’s assets exceeds the amount that will be required to be paid on or in respect of the Company’s existing debts and other liabilities (including known contingent liabilities) as they mature, (ii) the Company’s assets do not constitute unreasonably small capital to carry on its business as now conducted and as proposed to be conducted including its capital needs taking into account the particular capital requirements of the business conducted by the Company, consolidated and projected capital requirements and capital availability thereof, and (iii) the current cash flow of the Company, together with the proceeds the Company would receive, were it to liquidate all of its assets, after taking into account all anticipated uses of the cash, would be sufficient to pay all amounts on or in respect of its liabilities when such amounts are required to be paid. The Company does not intend to incur debts beyond its ability to pay such debts as they mature (taking into account the timing and amounts of cash to be payable on or in respect of its debt). The Company has no knowledge of any facts or circumstances which lead it to believe that it will file for reorganization or liquidation under the bankruptcy or reorganization laws of any jurisdiction within one year from the closing of the Inducement Offer. For the purposes hereof, “Indebtedness” means (x) any liabilities for borrowed money or amounts owed in excess of $50,000 (other than trade accounts payable incurred in the ordinary course of business), (y) all guaranties, endorsements and other contingent obligations in respect of indebtedness of others, whether or not the same are or should be reflected in the Company’s consolidated balance sheet (or the notes thereto), except guaranties by endorsement of negotiable instruments for deposit or collection or similar transactions in the ordinary course of business; and (z) the present value of any lease payments in excess of $50,000 due under leases required to be capitalized in accordance with GAAP. Neither the Company nor any Subsidiary is in default with respect to any Indebtedness.

EX-99.1 5 ptn_ex991.htm PRESS RELEASE ptn_ex991.htm

EXHIBIT 99.1

Palatin Announces Exercise of Warrants for Approximately $6.1 Million Gross Proceeds

CRANBURY, N.J., June 21, 2024 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN) (“Palatin” or the “Company”), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced that it has entered into a warrant inducement agreement with an institutional investor to exercise certain outstanding warrants that the Company issued in November 2022 and October 2023 totaling 3,233,277 shares of the Company’s common stock for gross proceeds of approximately $6.1 million.

Pursuant to the warrant inducement agreement, the investor has agreed to exercise November 2022 outstanding warrants to purchase an aggregate of 1,818,812 shares of the Company's common stock and has agreed to exercise October 2023 outstanding warrants to purchase an aggregate of 1,415,095 shares of the Company’s common stock, both sets at an amended exercise price of $1.88 per share. In consideration for the immediate exercise of the warrants, the Company also agreed to issue the investor unregistered Series A warrants to purchase an aggregate of 2,727,273 shares of the Company's common stock, and Series B warrants to purchase an aggregate of 2,122,642 shares of the Company’s common stock. The Series A and B warrants will each have an exercise price of $1.88 per share and will expire on the five-year anniversary of the closing date. The Series A warrants and 498,441 of the Series B warrants are exercisable immediately, with 1,624,201 shares of common stock underlying the Series B warrants exercisable beginning on the effective date of stockholder approval and will expire on the five-year anniversary from the date of stockholder approval.

The transaction is expected to close on or about June 24, 2024, subject to the satisfaction of customary closing conditions. The Company intends to use the net proceeds from the exercise of warrants for working capital and general corporate purposes.

The Series A and B warrants described above are being issued pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and Regulation D promulgated thereunder and, along with the shares of common stock underlying such warrants, have not been registered under the Securities Act, or applicable state securities laws.

This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities in this offering, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Palatin

Palatin is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor systems, with targeted, receptor-specific product candidates for the treatment of diseases with significant unmet medical need and commercial potential. Palatin’s strategy is to develop products and then form marketing collaborations with industry leaders to maximize their commercial potential. For additional information regarding Palatin, please visit Palatin’s website at www.Palatin.com and follow Palatin on Twitter at @PalatinTech.

Forward-looking Statements

Statements in this press release that are not historical facts, including statements related to the timing and completion of the offering, the satisfaction of customary closing conditions related to the offering and the intended use of proceeds therefrom, are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995. Palatin intends that such forward-looking statements be subject to the safe harbors created thereby. Forward-looking statements reflect the Company’s current views with respect to future events and are based on assumptions and subject to known and unknown risks and uncertainties, which change over time, and other factors that may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include, without limitation, market and other conditions,; the anticipated use of proceeds from the offering; results of clinical trials; regulatory actions by the FDA and other regulatory and the need for regulatory approvals; Palatin’s ability to fund development of its technology and establish and successfully complete clinical trials; the length of time and cost required to complete clinical trials and submit applications for regulatory approvals; products developed by competing pharmaceutical, biopharmaceutical and biotechnology companies; commercial acceptance of Palatin’s products; and other factors discussed in Palatin’s periodic filings with the SEC. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement, whether as a result of new information, future events or otherwise unless required by law.

Investor Inquiries:		Media Inquiries:
Stephen T. Wills, CPA, MST		Paul Arndt, MBA, LifeSci Advisors
CFO/COO (609) 495-2200		Managing Director (646) 597-6992
Info@Palatin.com		Paul@LifeSciAdvisors.com

Palatin Technologies® is a registered trademark of Palatin Technologies, Inc.

EX-101.SCH 6 ptn-20240620.xsd XBRL TAXONOMY EXTENSION SCHEMA 000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 7 ptn-20240620_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Entity Registrant Name Entity Central Index Key Document Type Amendment Flag Entity Emerging Growth Company Document Period End Date Entity File Number Entity Incorporation State Country Code Entity Tax Identification Number Entity Address Address Line 1 Entity Address City Or Town Entity Address State Or Province Entity Address Postal Zip Code City Area Code Local Phone Number Security 12b Title Trading Symbol Security Exchange Name Written Communications Soliciting Material Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer EX-101.CAL 8 ptn-20240620_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.PRE 9 ptn-20240620_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE EX-101.DEF 10 ptn-20240620_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE XML 12 R1.htm IDEA: XBRL DOCUMENT

Cover	Jun. 20, 2024
Cover [Abstract]
Entity Registrant Name	Palatin Technologies, Inc.
Entity Central Index Key	0000911216
Document Type	8-K
Amendment Flag	false
Entity Emerging Growth Company	false
Document Period End Date	Jun. 20, 2024
Entity File Number	001-15543
Entity Incorporation State Country Code	DE
Entity Tax Identification Number	95-4078884
Entity Address Address Line 1	4B Cedar Brook Drive
Entity Address City Or Town	Cranbury
Entity Address State Or Province	NJ
Entity Address Postal Zip Code	08512
City Area Code	609
Local Phone Number	495-2200
Security 12b Title	Common Stock, par value $0.01 per share
Trading Symbol	PTN
Security Exchange Name	NYSE
Written Communications	false
Soliciting Material	false
Pre Commencement Tender Offer	false
Pre Commencement Issuer Tender Offer	false

EXCEL 13 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 14 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 15 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 17 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.1.u2 html 1 22 1 false 0 0 false 3 false false R1.htm 000001 - Document - Cover Sheet http://ptn.com/role/Cover Cover Cover 1 false false All Reports Book All Reports ptn-20240620.xsd ptn-20240620_cal.xml ptn-20240620_def.xml ptn-20240620_lab.xml ptn-20240620_pre.xml ptn_8k.htm http://xbrl.sec.gov/dei/2023 true true JSON 19 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ptn_8k.htm": { "nsprefix": "ptn", "nsuri": "http://ptn.com/20240620", "dts": { "schema": { "local": [ "ptn-20240620.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/currency/2023/currency-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/exch/2023/exch-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd", "https://xbrl.sec.gov/sic/2023/sic-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] }, "calculationLink": { "local": [ "ptn-20240620_cal.xml" ] }, "definitionLink": { "local": [ "ptn-20240620_def.xml" ] }, "labelLink": { "local": [ "ptn-20240620_lab.xml" ] }, "presentationLink": { "local": [ "ptn-20240620_pre.xml" ] }, "inline": { "local": [ "ptn_8k.htm" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 23, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://ptn.com/role/Cover", "longName": "000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "From2024-06-20to2024-06-20", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "strong", "p", "td", "tr", "tbody", "table", "body", "html" ], "reportCount": 1, "baseRef": "ptn_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-06-20to2024-06-20", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "strong", "p", "td", "tr", "tbody", "table", "body", "html" ], "reportCount": 1, "baseRef": "ptn_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://ptn.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://ptn.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://ptn.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://ptn.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://ptn.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address Address Line 1", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://ptn.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address City Or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://ptn.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://ptn.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address State Or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://ptn.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://ptn.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://ptn.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://ptn.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://ptn.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://ptn.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://ptn.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://ptn.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://ptn.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://ptn.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security 12b Title", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://ptn.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://ptn.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://ptn.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://ptn.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 20 0001654954-24-008011-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001654954-24-008011-xbrl.zip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end XML 22 ptn_8k_htm.xml IDEA: XBRL DOCUMENT 0000911216 2024-06-20 2024-06-20 iso4217:USD shares iso4217:USD shares 0000911216 false 8-K 2024-06-20 Palatin Technologies, Inc. DE 001-15543 95-4078884 4B Cedar Brook Drive Cranbury NJ 08512 609 495-2200 false false false false Common Stock, par value $0.01 per share PTN NYSE false